This study focuses on preparing the secretory recombinant J subgroup of avian leukosis virus (ALV-J) gp85
protein using Pichia pastoris and evaluating its immunoprotection as vaccine antigen combining with CpGODN
adjuvant. The secretory recombinant plasmid pPIC9-gp85 containing ALV-J gp85 gene was designed and
was transfected into the genome of P. pastoris (GS115) cells. The recombinant plasmid was expressed under the
induction of methanol. The expressed products in the medium of the cells were purified and identified with
endoglycosidase digestion assay and western blot mediated with monoclonal antibody (MAb) JE9. The purified
product combining with CpG-ODN adjuvant was inoculated intramuscularly into 7-... More
This study focuses on preparing the secretory recombinant J subgroup of avian leukosis virus (ALV-J) gp85
protein using Pichia pastoris and evaluating its immunoprotection as vaccine antigen combining with CpGODN
adjuvant. The secretory recombinant plasmid pPIC9-gp85 containing ALV-J gp85 gene was designed and
was transfected into the genome of P. pastoris (GS115) cells. The recombinant plasmid was expressed under the
induction of methanol. The expressed products in the medium of the cells were purified and identified with
endoglycosidase digestion assay and western blot mediated with monoclonal antibody (MAb) JE9. The purified
product combining with CpG-ODN adjuvant was inoculated intramuscularly into 7-day-old chickens and three
booster inoculations were performed on 21 days post first inoculation (dpfi), 42, and 56 dpfi. The antibody
responses and cellular immune responses were detected, and the protective effects were analyzed after challenge
with ALV-J. The results showed that the secretory pPIC9-gp85 plasmid was successfully constructed and
could be stably expressed in GS115 cells. The expressed products were N-acetylglucosylated and could specifically
combine with MAb ( JE9). The secreted gp85 protein combining with CpG-ODN adjuvant could
induce higher antibody response and spleen lymphocyte proliferation response and IFN-c-inducing response,
and could protect all the inoculated chickens against the viremia and the immunosuppressive lesions caused by
ALV-J challenge. The results of neutralizing test in vitro suggested that the antisera with some ALV-J antibody
titers could neutralize ALV-J strain and inhibit the growth of virus in vitro. The result of IFA showed that IgG
antibody in the antisera could specifically combine with ALV-J strain in cells. It can be concluded that the
secretory recombinant gp85 protein, as a new acetylglucosylated gp85 protein, was successfully prepared and
combining with CpG-ODN adjuvant could protect the inoculated chickens against ALV-J infection. This study
first reported the methods on preparing the secretory recombinant ALV-J gp85 protein using P. pastoris and
evaluated its immunoprotection.